Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. März 2026 07:30 ET | Quelle: Marvel Biosciences Corp.

Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204

Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204
25. März 2026 07:30 ET | Quelle: Marvel Biosciences Corp.

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist
11. Dezember 2024 07:00 ET | Quelle: ProQR Therapeutics N.V.

ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
12. Januar 2024 10:10 ET | Quelle: Block & Leviton LLP

Anavex Life Sciences Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for potential securities law violations. Investors who have lost money in...
05. Januar 2024 07:00 ET | Quelle: ProQR Therapeutics N.V.

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the...
03. Januar 2024 12:14 ET | Quelle: Block & Leviton LLP

Anavex Life Sciences Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for potential securities law violations. Investors who have lost money in...
16. November 2022 17:05 ET | Quelle: Vyant Bio, Inc.

Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at Neuroscience 2022 Hosted by the Society for Neuroscience

“Targeting specific functional rescue in a Rett patient cortical organoid disease model” CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq:...
16. November 2022 16:43 ET | Quelle: Vyant Bio, Inc.

Vyant Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
10. November 2022 17:13 ET | Quelle: Vyant Bio, Inc.

Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at the 2022 CDKL5 Forum Hosted by the Loulou Foundation

CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
27. Oktober 2022 17:10 ET | Quelle: Vyant Bio, Inc.

Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022

Platform and Poster Presentations on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY HILL, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Vyant...

Nächste Seite